Relay Therapeutics, Inc.
HealthcareNASDAQ:RLAY · NASDAQ Global Market
+$0.57 today
Vol 1.77M · Avg 3.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-48.8%
avg -16.8%
ROIC
-50.5%
avg -31.0%
ROA
-44.5%
avg -27.6%
Analysis
ROA is currently the strongest return metric at -44.5% versus its period average of -27.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sanjiv K. Patel MBBS | Chief Executive Officer, President & Director | $1.13M | — | 52 | $1.45M | 0.83% |
Donald A. Bergstrom | President of Research & Development | $817,663.00 | — | 54 | $418,557.00 | 0.24% |
Thomas Catinazzo | Chief Financial Officer | $694,113.00 | — | 49 | $195,178.00 | 0.11% |
Peter Rahmer | Chief Corporate Development Officer | $670,670.00 | — | 44 | $275,857.00 | 0.16% |
Mark Murcko | Founder & Independent Director | $65,924.00 | — | 66 | $32,947.00 | 0.02% |
Soo-Yeun Lim | Senior Vice President & General Counsel | — | — | — | — | — |
David Elliot Shaw | Founder | — | — | 75 | — | — |
Matthew Jacobson | Founder | — | — | — | — | — |
Dorothee Kern | Founder | — | — | — | — | — |
Mahesh Padval | Chief Pharmaceutical Development Officer | — | — | — | — | — |
Brenton Mar | Senior Vice President of Clinical Development | — | — | — | — | — |
Jim Watters | Chief Scientific Officer | — | — | — | — | — |
Imogen Pryce | Chief Operating Officer of R&D | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$3.10M
Net Sentiment
$3.10M
Net selling
Most Active
Catinazzo Thomas
10 transactions
1–10 of 29
Analysis
Insiders reported 0 buys worth $0.00 and 29 sells worth $3.10M over the last 12 months. That adds up to net selling of $3.10M. Catinazzo Thomas was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | +107.1% (8yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +107.1% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Upstream Bio, Inc.
UPB
$331.96M
Who manages RLAY?
Relay Therapeutics, Inc. (RLAY) lists 13 active executives. The top listed executive is Soo-Yeun Lim, Senior Vice President & General Counsel.
Are RLAY insiders buying or selling?
Recent insider activity shows net buying of $41.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.